0001437749-19-011280.txt : 20190603 0001437749-19-011280.hdr.sgml : 20190603 20190603164354 ACCESSION NUMBER: 0001437749-19-011280 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190603 DATE AS OF CHANGE: 20190603 EFFECTIVENESS DATE: 20190603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diffusion Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001053691 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300645032 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-341007 FILM NUMBER: 19873838 BUSINESS ADDRESS: STREET 1: 2020 AVON COURT STREET 2: SUITE 4 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 BUSINESS PHONE: (434) 220-0718 MAIL ADDRESS: STREET 1: 2020 AVON COURT STREET 2: SUITE 4 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 FORMER COMPANY: FORMER CONFORMED NAME: RestorGenex Corp DATE OF NAME CHANGE: 20140307 FORMER COMPANY: FORMER CONFORMED NAME: Stratus Media Group, Inc DATE OF NAME CHANGE: 20080722 FORMER COMPANY: FORMER CONFORMED NAME: FERIS INTERNATIONAL, INC. DATE OF NAME CHANGE: 20080228 D 1 primary_doc.xml X0708 D LIVE 0001053691 Diffusion Pharmaceuticals Inc. 1317 CARLTON AVENUE SUITE 200 CHARLOTTESVILLE VA VIRGINIA 22902 (434) 220-0718 DELAWARE None RestorGenex Corp Stratus Media Group, Inc FERIS INTERNATIONAL, INC. Corporation true David G. Kalergis 1317 Carlton Avenue Suite 200 Charlottesville VA VIRGINIA 22902 Executive Officer Director Mark T. Giles 1317 Carlton Avenue Suite 200 Charlottesville VA VIRGINIA 22902 Director John L. Gainer 1317 Carlton Avenue Suite 200 Charlottesville VA VIRGINIA 22902 Executive Officer Director Robert W. Adams 1317 Carlton Avenue Suite 200 Charlottesville VA VIRGINIA 22902 Director Alan G. Levin 1317 Carlton Avenue Suite 200 Charlottesville VA VIRGINIA 22902 Director William K. Hornung 1317 Carlton Avenue Suite 200 Charlottesville VA VIRGINIA 22902 Executive Officer Thomas S. Byrne 1317 Carlton Avenue Suite 200 Charlottesville VA VIRGINIA 22902 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2019-05-23 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue 4th Floor New York NY NEW YORK 10022 All States true 164132 164132 0 false 3 13131 true 0 H.C. Wainwright & Co., LLC will also receive a 5-year warrant to purchase up to 65,853 shares of common stock. 0 A portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3. true Diffusion Pharmaceuticals Inc. /s/ David G. Kalergis David G. Kalergis Chairman and CEO 2019-06-03